The novel central hypothesis of this proposal is that the Quality of Life in Neurological Disorders (Neuro-QoL), a patient-reported outcome (PRO) battery of questionnaires, can fill this gap in screening for clinical decision-making. Our strong preliminary data demonstrate that the cognitive short form within the Neuro-QoL (NQ-CSF) provides a simple yet critically needed screening tool for use in aSAH survivors; however, this instrument has not yet been tested a) as a benchmark to trigger individual patient referral for in-depth neuropsychological assessment; b) for interpretation in relation to other relevant demographic and clinical information; or c) for interpretation in relation to other Neuro-QoL measures. We respond here to PA-19-053 and NOT-OD-20-079, and the spirit of PAR-22-231, to propose one highly focused aim: Determine the utility of the Neuro-QoL cognition short form (NQ-CSF) as a benchmark to trigger individual patient referral for in-depth clinical neuropsychological assessment. This project is innovative for applying the Neuro-QoL for clinically meaningful cognitive symptom screening and individualized patient referral post-aSAH. The work will have a significant impact by informing new practice guidelines to provide earlier and more accurate assessment of cognitive symptomatology. Lack of such knowledge reduces QoL for patients affected by aSAH.